Intravenous BIBH 1 in Patients With Metastatic Colorectal Cancer
NCT02198274 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25
Last updated 2014-07-23
Summary
Study to evaluate the anti-tumour activity, safety and pharmacokinetics of unlabelled sibrotuzumab administered weekly (seven days +/- one day) at a dose of 100 mg (a total of 12 administrations) in patients with metastatic colorectal cancer.
Conditions
- Colorectal Neoplasms
Interventions
- DRUG
-
BIBH 1
100 mg/week
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2000-02-29
- Primary Completion
- 2000-10-31
More Related Trials
-
A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer
NCT00483834 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
NCT05609370 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
An Observational Study of Bevacizumab in Combination With 5-FU-Based Chemotherapy in Chinese Participants With Metastatic Colorectal Cancer
NCT01319877 ·Status: COMPLETED
-
A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas
NCT06882746 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of Bevacizumab Plus 5-Flurouracil (5-FU) Based Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer
NCT01695772 ·Status: COMPLETED ·Phase: PHASE4
-
Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer
NCT04194359 ·Status: UNKNOWN ·Phase: PHASE2
-
Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer
NCT00077298 ·Status: COMPLETED ·Phase: PHASE2
-
Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer
NCT06192680 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Cetuximab for Elderly Patients With mCRC
NCT01718808 ·Status: TERMINATED ·Phase: PHASE2
-
BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer
NCT00326495 ·Status: COMPLETED ·Phase: PHASE2
-
SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab in First-line Treatment of mCRC
NCT05438108 ·Status: UNKNOWN ·Phase: PHASE2
-
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
NCT01538680 ·Status: NO_LONGER_AVAILABLE
-
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
NCT01776307 ·Status: COMPLETED ·Phase: PHASE2
-
SB-715992 in Treating Patients With Advanced or Metastatic Colorectal Cancer
NCT00103311 ·Status: COMPLETED ·Phase: PHASE2
-
Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
NCT00467142 ·Status: COMPLETED ·Phase: PHASE2
-
BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer
NCT00904839 ·Status: COMPLETED ·Phase: PHASE2
-
Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal Cancer
NCT02776683 ·Status: COMPLETED ·Phase: PHASE3
-
Bevacizumab-containing Regimen for Metastatic Colorectal Cancer Failed to Cytotoxic Treatment
NCT02226289 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy and Safety of Triweekly Cetuximab in Combination With Capecitabine as First-line Maintenance Treatment for KRAS/BRAF Wild-type Metastatic Colorectal Cancer
NCT05775900 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer.
NCT00778102 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma
NCT00102024 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer
NCT03307603 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer
NCT06184698 ·Status: RECRUITING ·Phase: PHASE2
-
Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer
NCT01875380 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I/II Combination With Irinotecan- Erbitux
NCT00594984 ·Status: COMPLETED ·Phase: PHASE1/PHASE2